摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-氯2,1,3-苯并恶唑-4磺酰氯 | 175203-78-8

中文名称
5-氯2,1,3-苯并恶唑-4磺酰氯
中文别名
5-氯-2,1,3-苯并氧二唑-4-磺酰氯
英文名称
5-chloro-2,1,3-benzoxadiazole-4-sulfonyl chloride
英文别名
——
5-氯2,1,3-苯并恶唑-4磺酰氯化学式
CAS
175203-78-8
化学式
C6H2Cl2N2O3S
mdl
MFCD00203878
分子量
253.065
InChiKey
ZFBZICACMDZKNQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    73 °C

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    81.4
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 危险等级:
    MOISTURE SENSITIVE, CORROSIVE
  • 危险品标志:
    Xi,C
  • 危险类别码:
    R34
  • 海关编码:
    2934999090
  • 安全说明:
    S26,S36/37/39,S45

SDS

SDS:9979b8bfb86bb84e69519665e18f0068
查看
Name: 5-Chloro-2 1 3-benzoxadiazole-4-sulfonyl chloride 97% Material Safety Data Sheet
Synonym: 5-Chlorobenzofurazan-4-sulfonyl chlorid
CAS: 175203-78-8
Section 1 - Chemical Product MSDS Name:5-Chloro-2 1 3-benzoxadiazole-4-sulfonyl chloride 97% Material Safety Data Sheet
Synonym:5-Chlorobenzofurazan-4-sulfonyl chlorid

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
175203-78-8 5-Chloro-2,1,3-benzoxadiazole-4-sulfon 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175203-78-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 73 - 75 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H2Cl2N2O3S
Molecular Weight: 253.07

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175203-78-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Chloro-2,1,3-benzoxadiazole-4-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 175203-78-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175203-78-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175203-78-8 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor
    摘要:
    Hypoxia inducible factors (HIFs) are heterodimeric transcription factors induced in a variety of pathophysiological settings, including cancer. We describe the first detailed structure-activity relationship study of small molecules designed to inhibit HIF-2 alpha-ARNT heterodimerization by binding an internal cavity of the HIF-2 alpha PAS-B domain. Through a series of biophysical characterizations of inhibitor-protein interactions (NMR and X-ray crystallography), we have established the structural requirements for artificial inhibitors of the HIF-2 alpha-ARNT PAS-B interaction. These results may serve as a foundation for discovering therapeutic agents that function by a novel mode of action.
    DOI:
    10.1021/jm301847z
点击查看最新优质反应信息

文献信息

  • N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20100197703A1
    公开(公告)日:2010-08-05
    This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.
    该发明提供了噻唑基哌嗪衍生物,以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物,以及其药学上可接受的盐,这些是用于治疗α-突触核蛋白病的有效活性成分,如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法,以及包括这些衍生物和药学上可接受的辅料的药物组合物。
  • Chemical compounds
    申请人:Adams Leroy Jerry
    公开号:US20050004142A1
    公开(公告)日:2005-01-06
    Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
    本文描述了作为TIE-2和/或VEGFR-2抑制剂有用的呋喃和噻吩嘧啶衍生物。所述发明还包括制备这种呋喃和噻吩嘧啶衍生物的方法,以及使用它们治疗增殖过度性疾病的方法。
  • Piperazines as P2X7 antagonists
    申请人:Betschmann Patrick
    公开号:US20080076924A1
    公开(公告)日:2008-03-27
    Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
    化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药,其中取代基如本文所定义,这些化合物可用作治疗剂。
  • Process for the preparation of oxazolidinones and method of use thereof
    申请人:Hollingsworth I. Rawle
    公开号:US20070265451A1
    公开(公告)日:2007-11-15
    A process for preparing N-(substituted)-C-(substituted methyl)-oxazolidinones, C-(substituted methyl)-oxazolidinones, and N-(substituted)-C-(substituted methyl)-oxazolidinones, preferably chiral, from optically active C-(protected oxymethyl)-oxazolidinones is described. The process can be used to produce combinatorial libraries of the above substituted oxazolidinones in a two or three step reaction comprising a plurality of reagents differing in numbers of carbons or particular substituted oxazolidinones. A number of substituted oxazolidinones produced using the above process have been discovered to have antimicrobial activity.
    本文介绍了一种从光学活性的C-(保护的氧甲基)-噁唑烷酮制备N-(取代)-C-(取代甲基)-噁唑烷酮、C-(取代甲基)-噁唑烷酮和N-(取代)-C-(取代甲基)-噁唑烷酮的方法,其中优选手性化合物。该方法可用于在包含多种碳数或特定取代噁唑烷酮的多种试剂的两步或三步反应中产生上述取代噁唑烷酮的组合库。使用上述方法生产的许多取代噁唑烷酮已被发现具有抗微生物活性。
  • PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF
    申请人:Hollingsworth Rawle I.
    公开号:US20080146458A1
    公开(公告)日:2008-06-19
    Substituted oxazolidinone of the formula: wherein R 2 is alkyl selected from the group consisting of methyl, ethyl, and isopropyl moieties, are described. The compounds are antibacterial.
    描述了以下化学式的氧杂环丙酮类替代物:其中R2是选择自甲基,乙基和异丙基基团的烷基。这些化合物具有抗菌作用。
查看更多

同类化合物

重氮二硝基苯酚 达罗地平 苯并芙咱-5-硼酸频那醇酯 苯并氧化呋咱-5-羧酸 苯并呋扎-5-甲腈 苯并呋喃-5-磺酰氯 苯并呋喃-5-甲酸乙酯 苯并呋喃 苯并呋咱-5-羧酸乙酯 苯并呋咱-5-羧酸 苯并呋咱-5-碳酰氯 苯并呋咱 苯并二唑-4-甲醛 苯呋咱-5-三氟硼酸钾 硝基氨基吡咯烷苯并恶嗪 哌嗪酮,6-甲基-5-硫代-,(R)-(9CI) 去甲基伊拉地平 伊拉地平内酯 伊拉地平EP杂质A 伊拉地平 乙酮,1-[5-(丁基氨基)-2-羟基苯基]- NBD-双十六胺 N-[12-[((7-硝基-2-1,3-苯并恶二唑-4-基)氨基]十二烷酰基]-D-赤型-鞘氨醇 N-7-(4-硝基苯并-2-氧代-1,3-二氮唑)-omega-氨基己酸beta-(N-三甲基铵)乙酯 N-(7-硝基苯并-2-氧杂-1,3-二氮唑-4-基)磷脂酰乙醇胺 N-(3-氯-5-氟苯基)-4-硝基-2,1,3-苯并恶二唑-5-胺 N-(2-吗啉基乙基)-7-硝基-2,1,3-苯并恶二唑-4-胺 N,N-二甲基-7-硝基苯并呋咱-4-胺 N,N-二丁基-7-硝基-4-苯并呋咱胺 N'-[5-[[4-[5-(乙酰基-羟基氨基)戊基氨基]-4-氧代丁酰基]-羟基氨基]戊基]-N-羟基-N-[5-[(4-硝基-2,1,3-苯并恶二唑-7-基)氨基]戊基]丁二酰胺 8-异米索前列醇 7-肼-N,N-二-4-苯并呋咱磺 7-硝基-N-[2-(2-吡啶基二硫代)乙基]-2,1,3-苯并恶二唑-4-胺 7-硝基-1-氧代-2,1,3-苯并恶二唑-1-鎓 7-甲氧基-2,1,3-苯并恶二唑-4-磺酰氯 7-氯苯并[c][1,2,5]噁二唑-4-胺 7-氯-N,N-二乙基-4-硝基-2,1,3-苯并恶二唑-5-胺 7-氯-4-硝基-5-哌啶基-2,1,3-苯并噁二唑 7-氯-4-硝基-2,1,3-苯并噁二唑1-氧化 7-氯-2,1,3-苯并噁二唑-4-磺酸 7-氟苯呋咱-4-磺酰胺 7-氟苯呋咱-4-硫氨 7-氟-2,1,3-苯并恶二唑-4-磺酰氯 7-哌啶-1-基-2,1,3-苯并恶二唑-4-胺 7-吗啉-4-基苯并[1,2,5]恶二唑-4-基胺 6-溴苯并[c][1,2,5]噁二唑1-氧化物 6-氟-2,1,3-苯并恶二唑-5-胺 6-[[7-(N,N-二甲氨基磺酰)-2,1,3-苯并恶二唑-4-基]氨基]己酸琥珀酰亚胺酯 6-[(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]己酸 6,7-二氢-1,2,3,10-四甲氧基-7-[甲基(7-硝基-2,1,3-苯并恶二唑-4-基)氨基]-(7S)-苯并[a]庚搭烯-9(5H)-酮